other material
confidence high
sentiment positive
materiality 0.82
Altimmune reports Phase 2 obesity trial: 15.6% mean weight loss with pemvidutide 2.4 mg at Week 48
Altimmune, Inc.
- Mean weight loss of 15.6% on 2.4 mg dose vs 2.2% placebo; near-linear trajectory at end of treatment.
- Over 30% of subjects achieved ≥20% weight loss on 2.4 mg; 83.9% achieved ≥5% weight loss.
- Robust reductions in serum lipids and blood pressure without cardiac safety imbalances; zero MACE events.
- Discontinuation rates higher at higher doses: 19.6% (2.4 mg) vs 6.2% placebo; most due to GI AEs in first 16 weeks.
- Only one drug-related SAE (vomiting at 2.4 mg); nausea/vomiting predominantly mild to moderate.